Health
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
New analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led research in pregnancyLate-breaking comparative data vs. rapid-acting insulin analogs to be presented June 7Nine posters showcase new clinical and real-world insights across dosing approaches, glycemic control, and patient-reported experience PDUFA target action date for Afrezza in children and adolescents living with diabetes set for May 29, 2026 DANBURY, C
About this update from Mannkind Corporation
[{"type":"image","alt":"MannKind","displaySize":"","headline":null,"caption":"MannKind","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/25877a202ba02abe901e1a60c89ab7e1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rnJ2dlyjbOeUw2hiS_KryQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/25877a202ba02abe901e1a60c89ab7e1","width":300,"height":157},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/rnJ2dlyjbOeUw2hiS_KryQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/25877a202ba02abe901e1a60c89ab7e1","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led research in pregnancy","length":162,"tagName":"p"}]},{"val":[{"type":"text","content":"Late-breaking comparative data vs. rapid-acting insulin analogs to be presented June 7","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Nine posters showcase new clinical and real-world insights across dosing approaches, glycemic control, and patient-reported experience ","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"PDUFA target action date for Afrezza in children and adolescents living with diabetes set for May 29, 2026","length":106,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":488,"olType":false},{"type":"text","content":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that new clinical and real‑world data related to Afrezza® (insulin human) Inhalation Powder along with analyses of FUROSCIX® (furosemide injection) in patients with co-morbidities will be presented at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place June 5-8, 2026, in New Orleans, Louisiana.","length":622,"tagName":"p"},{"type":"text","content":"“As we approach the upcoming FDA target action date of Afrezza for pediatric patients, these new data further strengthen our u...